Literature DB >> 24390326

T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice.

Frank Heuts1, Martin E Rottenberg, Daniel Salamon, Eahsan Rasul, Monika Adori, George Klein, Eva Klein, Noemi Nagy.   

Abstract

UNLABELLED: Human B cells, the main target of Epstein-Barr virus (EBV), can display several types of latent viral protein expression, denoted 0, I, IIa, IIb, or III. Of these, only type III expression induces proliferation of cells in vitro. These latency types are present at specific stages of infection and are also characteristic of different tumor types, but their generation is not fully understood. In this study, we analyzed the role of T cells in the regulation of EBV viral latency by using humanized NOD/SCID/IL2Rγ(-/-) mice. Several spleens presented macroscopic tumors 4 weeks after infection. Explanted spleen B cells from some of the EBV-infected mice proliferated in vitro, but this was usually lowered when cyclosporine was added to the cultures. This suggested that the in vitro growth of EBV-infected B cells required T cell help; thus, cells other than type III cells were also present in the spleens. Quantitative PCR analysis of promoter activities specific for the different EBV latency types confirmed that in addition to type III cells, type IIa and type I cells were present in the spleen. The relative usage of the viral promoter specific for I and IIa latency types (Q promoter) was higher in CD8(+) cell-depleted mice, and it was absent from CD4(+) cell-depleted mice. These results indicate that CD4(+) T cells are necessary for the generation/maintenance of cells with latency I/IIa in the humanized mice. CD4(+) T cells contributed to this process through their CD40L expression. IMPORTANCE: At primary infection with EBV, the infected B cells are proliferating and express viral proteins that have transforming potential. However, when the acute infection is resolved, in healthy individuals EBV is carried by a small fraction of B cells that express a restricted number of viral proteins unable to induce proliferation. Understanding the details of this transition is of fundamental importance. We studied this question in humanized mice by manipulating their different T cell compartments before and during infection with EBV. Our results indicate that CD4(+) T cells are responsible for the switch to a nonproliferating EBV program during primary infection with EBV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390326      PMCID: PMC3957948          DOI: 10.1128/JVI.02885-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes.

Authors:  Arvind Raghavan; Rachel L Ogilvie; Cavan Reilly; Michelle L Abelson; Shalini Raghavan; Jayprakash Vasdewani; Mitchell Krathwohl; Paul R Bohjanen
Journal:  Nucleic Acids Res       Date:  2002-12-15       Impact factor: 16.971

2.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

3.  STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma.

Authors:  Loránd L Kis; Natalija Gerasimcik; Daniel Salamon; Emma K Persson; Noémi Nagy; George Klein; Eva Severinson; Eva Klein
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

4.  Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice.

Authors:  Leonard D Shultz; Yoriko Saito; Yuho Najima; Satoshi Tanaka; Toshiki Ochi; Mariko Tomizawa; Takehiko Doi; Akiko Sone; Nahoko Suzuki; Hiroshi Fujiwara; Masaki Yasukawa; Fumihiko Ishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  Large clonal expansions of CD8+ T cells in acute infectious mononucleosis.

Authors:  M F Callan; N Steven; P Krausa; J D Wilson; P A Moss; G M Gillespie; J I Bell; A B Rickinson; A J McMichael
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  T cell-mediated control of Epstein-Barr virus infection in humanized mice.

Authors:  Misako Yajima; Ken-Ichi Imadome; Atsuko Nakagawa; Satoru Watanabe; Kazuo Terashima; Hiroyuki Nakamura; Mamoru Ito; Norio Shimizu; Naoki Yamamoto; Shigeyoshi Fujiwara
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

7.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

Authors:  R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.

Authors:  Henry H Balfour; Oludare A Odumade; David O Schmeling; Beth D Mullan; Julie A Ed; Jennifer A Knight; Heather E Vezina; William Thomas; Kristin A Hogquist
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

9.  Infectious mononucleosis and Hodgkin's disease.

Authors:  N Muñoz; R J Davidson; B Witthoff; J E Ericsson; G De-Thé
Journal:  Int J Cancer       Date:  1978-07-15       Impact factor: 7.396

Review 10.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

View more
  14 in total

Review 1.  Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.

Authors:  Donal McHugh; Nicole Caduff; Anita Murer; Christine Engelmann; Yun Deng; Hana Zdimerova; Kyra Zens; Obinna Chijioke; Christian Münz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

2.  HIV co-infection augments EBV-induced tumorigenesis in vivo.

Authors:  Christopher B Whitehurst; Monica Rizk; Adonay Teklezghi; Rae Ann Spagnuolo; Joseph S Pagano; Angela Wahl
Journal:  Front Virol       Date:  2022-03-11

3.  Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.

Authors:  Carrie B Coleman; Julie Lang; Lydia A Sweet; Nicholas A Smith; Brian M Freed; Zenggang Pan; Bradley Haverkos; Roberta Pelanda; Rosemary Rochford
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

Review 4.  Study of viral pathogenesis in humanized mice.

Authors:  Jenna M Gaska; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2015-01-22       Impact factor: 7.090

Review 5.  Modeling EBV infection and pathogenesis in new-generation humanized mice.

Authors:  Shigeyoshi Fujiwara; Ken-Ichi Imadome; Masami Takei
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

Review 6.  Recent advances in understanding Epstein-Barr virus.

Authors:  Brent A Stanfield; Micah A Luftig
Journal:  F1000Res       Date:  2017-03-29

7.  EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.

Authors:  Christine T Styles; Quentin Bazot; Gillian A Parker; Robert E White; Kostas Paschos; Martin J Allday
Journal:  PLoS Biol       Date:  2017-08-03       Impact factor: 8.029

Review 8.  Application of Humanized Mice in Immunological Research.

Authors:  Wenwei Tu; Jian Zheng
Journal:  Methods Mol Biol       Date:  2016

Review 9.  Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2019-12-17

Review 10.  Probing Reconstituted Human Immune Systems in Mice With Oncogenic γ-Herpesvirus Infections.

Authors:  Christian Münz
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.